Behavioral effects of non-viral mediated RNA interference of synapsin II in the medial prefrontal cortex of the rat

Schizophrenia Research
Bailey A DyckR K Mishra

Abstract

Synapsin II is a synaptic vesicle-associated phosphoprotein that has been implicated in the pathophysiology of schizophrenia. Researchers have demonstrated reductions in synapsin II mRNA and protein in post-mortem prefrontal cortex and hippocampus samples from patients with schizophrenia. Synapsin II protein expression has been shown to be regulated by dopamine D(1) and D(2) receptor activation. Furthermore, behavioral testing of the synapsin II knockout mouse has revealed a schizophrenic-like behavioral phenotype in this mutant strain, suggesting a relationship between dysregulated and/or reduced synapsin II and schizophrenia. However, it remains unknown the specific regions of the brain of which perturbations in synapsin II play a role in the pathophysiology of this disease. The aim of this project was to evaluate animals with a selective knock-down of synapsin II in the medial prefrontal cortex through the use of siRNA technology. Two weeks after continuous infusion of synapsin II siRNAs, animals were examined for the presence of a schizophrenic-like behavioral phenotype. Our results reveal that rats with selective reductions in medial prefrontal cortical synapsin II demonstrate deficits in sensorimotor gating (prepulse inhi...Continue Reading

References

May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·H T KaoP Greengard
Jun 3, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F Sams-Dodd
Mar 23, 2000·Progress in Neurobiology·P CalabresiG Bernardi
Oct 24, 2001·Current Opinion in Oncology·K T FlahertyP J O'Dwyer
May 23, 2002·Cellular and Molecular Life Sciences : CMLS·A Ferreira, M Rapoport
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gwenaëlle Le Pen, Jean-Luc Moreau
Apr 16, 2003·European Journal of Biochemistry·Jens Kurreck
Sep 19, 2003·Biochemical and Biophysical Research Communications·James J CheethamLinda J Johnston
Apr 9, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Daniel GitlerGeorge J Augustine
Jun 26, 2004·Annual Review of Neuroscience·Thomas C Sudhof
Oct 30, 2004·The Journal of Gene Medicine·Zahra HassaniBarbara A Demeneix
Dec 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Deepak R ThakkerJohn F Cryan
Jan 22, 2005·Annual Review of Medicine·Derek M Dykxhoorn, Judy Lieberman
Dec 22, 2005·Current Medical Research and Opinion·R GoereeJ-E Tarride
Feb 17, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark A Behlke
May 16, 2007·Annals of Neurology·Federica LocatelliGiacomo Pietro Comi
Jun 2, 2007·Journal of Neurochemistry·Yann SenechalKumlesh K Dev
May 5, 2010·Progress in Neurobiology·F CescaF Benfenati

❮ Previous
Next ❯

Citations

Mar 20, 2013·Cellular and Molecular Life Sciences : CMLS·Lisa GherardiniTommaso Pizzorusso
May 23, 2015·Scientific Reports·Elimelech NesherAlbert Pinhasov
Jan 3, 2013·Behavioural Brain Research·Barbara GrecoFabio Benfenati
Aug 19, 2021·Neuroscience and Biobehavioral Reviews·Francesca LonghenaArianna Bellucci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain developing: Influences & Outcomes

This feed focuses on influences that affect the developing brain including genetics, fetal development, prenatal care, and gene-environment interactions. Here is the latest research in this field.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here